RSS

Braeburn Pharmaceuticals

The advisory committee of the US Food and Drug Administration (FDA) has recommended the approval of Braeburn Pharmaceutical’s investigational buprenorphine depot, CAM2038, for the treatment of opioid use disorder. more

News

With patient adherence and prevention of overdose hot topics for pharma, regulatory and healthcare sectors, the rise of implants for the sustained and controlled delivery of drugs is perhaps an inevitable trend. more

Opinion

The Psychopharmacologic Drugs Advisory Committee (PDAC) of the US Food and Drug Administration (FDA) has voted in favour of approving Probuphine, an implant to treat opioid addiction more

News